Key TakeawaysThe global vaccines market reached USD 87.57 billion in 2024 and is projected to grow to USD 206.78 billion by ...

Key TakeawaysThe global vaccines market reached USD 87.57 billion in 2024 and is projected to grow to USD 206.78 billion by 2035, representing a robust CAGR of 9.80%.Increasing prevalence of ...

LONDON, GREATER LONDON, UNITED KINGDOM, June 5, 2025 /EINPresswire.com/ -- The Business Research Company’s Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts ...

Pfizer’s Debt figure was $61 Bil at the end of the most recent quarter, while its market capitalization is $133 Bil (as of 6/2/2025). This implies a poor Debt-to-Equity Ratio of 46.2% (vs. 19.9% ...

Pfizer's dividend yield is around 7.3%, which is super generous. If you have an opening in your portfolio for a great stock with solid growth potential and perhaps even a respectable dividend ...

The past three years have been challenging for Pfizer (NYSE: PFE).Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022.

The past three years have been challenging for Pfizer (PFE 1.14%). Revenue and earnings have moved in the wrong direction, as has the company's share price. The stock is down by 56% since 2022.

Pfizer (NYSE:PFE) announced robust sales for the antifungal drug Cresemba in partnership with Basilea Pharmaceutica Ltd, marking significant growth in key Asian markets. Despite this achievement ...

Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, data that could change how physicians treat a particularly deadly form of ...

Pfizer appears to be a very promising stock to buy if you're looking for income. That 7.3% dividend yield is terrific, and even if it gets slashed, it will likely still be substantial.

Lately, Pfizer (PFE-0.08%) and Prologis (PLD-0.32%) have been perfect examples of the trade-off between attractive yields and dividend growth. Pfizer offers a sky-high yield that's climbing slowly.